Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Working Capital Changes (2021 - 2025)

Historic Other Working Capital Changes for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $3.2 million.

  • Amylyx Pharmaceuticals' Other Working Capital Changes rose 18390.21% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year increase of 7168.05%. This contributed to the annual value of -$5.0 million for FY2024, which is 25461.87% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Other Working Capital Changes of $3.2 million as of Q3 2025, which was up 18390.21% from -$5.9 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Other Working Capital Changes high stood at $6.3 million for Q3 2023, and its period low was -$5.9 million during Q2 2025.
  • Its 5-year average for Other Working Capital Changes is $244368.4, with a median of $421000.0 in 2021.
  • Data for Amylyx Pharmaceuticals' Other Working Capital Changes shows a peak YoY increase of 190409.84% (in 2022) and a maximum YoY decrease of 29881.24% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Other Working Capital Changes stood at $2.7 million in 2021, then decreased by 13.96% to $2.3 million in 2022, then crashed by 286.59% to -$4.4 million in 2023, then soared by 111.62% to $508000.0 in 2024, then surged by 534.06% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, -$5.9 million for Q2 2025, and -$666000.0 during Q1 2025.